<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03374956</url>
  </required_header>
  <id_info>
    <org_study_id>17-003449</org_study_id>
    <nct_id>NCT03374956</nct_id>
  </id_info>
  <brief_title>Individualized Obesity Pharmacotherapy</brief_title>
  <official_title>Individualized Pharmacological Approach to Obesity Management: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers are trying to identify the specific characteristics (phenotypes) that may be
      useful to help select the right medication for weight loss.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants will be phenotype and participants will randomized to randomly assigned
      medications vs phenotype guided medications for obesity. All participants will receive a
      standard intense lifestyle intervention.All participants will be seen at 4 and 12 weeks. At
      the 12-week visit, participants will be unblinded to their &quot;obesity-related phenotype&quot; and
      they could contact their physician to continue a FDA-approved medication as part of clinical
      care. Study team will prospectively follow the patients' weight, waist circumference and use
      of obesity medications every 3 months for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Body Weight Loss</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Change in body weight will be measured in kilograms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders</measure>
    <time_frame>baseline,4 weeks, 12 weeks</time_frame>
    <description>Percentage of participants who loss 5% or more of total body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders</measure>
    <time_frame>baseline, 12 weeks, 6 months, 12 months</time_frame>
    <description>Percentage of participants with at least 10% total body weight loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Percentage of participants with 15% total body weight loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders</measure>
    <time_frame>baseline, 4 weeks, 12 weeks</time_frame>
    <description>Percentage of participants who loss 5% or more of total body weight in each phenotype</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phenotype-guided pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine plus Exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomly assigned pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentermine-Topiramate</intervention_name>
    <description>Extended Release at dose of 7.5/46 mg oral daily</description>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Qsymia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>dose of 3 mg subcutaneous daily</description>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Saxenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone/bupropion</intervention_name>
    <description>Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)</description>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Contrave</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentermine</intervention_name>
    <description>15-37.5 mg oral daily</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Adipex-P</other_name>
    <other_name>Lomaira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Adults with obesity (BMI &gt;30 Kg/m2); these will be otherwise healthy individuals with
             no unstable psychiatric disease and controlled comorbidities or other diseases.

          -  Gender: Men or women. Women of childbearing potential will have negative pregnancy
             tests within 48 hours of enrollment and before each radiation exposure.

        Exclusion criteria

          -  Abdominal bariatric surgery

          -  Positive history of chronic gastrointestinal diseases, or systemic disease that could
             affect gastrointestinal motility, or use of medications that may alter
             gastrointestinal motility, appetite or absorption, e.g., orlistat, within the last 6
             months.

          -  Significant untreated psychiatric dysfunction based upon screening with the Hospital
             Anxiety and Depression Inventory (HAD), and the Questionnaire on Eating and Weight
             Patterns (binge eating disorders and bulimia). If such a dysfunction is identified by
             an anxiety or depression score &gt;11 or difficulties with substance or eating disorders,
             the participant will be excluded and given a referral letter to his/her primary care
             doctor for further appraisal and follow-up.

          -  Hypersensitivity to any of the study medications.

          -  No contraindications to all FDA-approved medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres J Acosta</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Davis</last_name>
      <phone>507-266-9447</phone>
      <email>RSTINDIVOBESITY@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Andres J Acosta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2017</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Andres J. Acosta, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pharmacological</keyword>
  <keyword>Obesity Management</keyword>
  <keyword>Individualized</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Phentermine</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

